Insight Molecular Diagnostics Stock Performance

IMDX Stock   6.64  0.05  0.75%   
Insight Molecular has a performance score of 1 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0435, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Insight Molecular's returns are expected to increase less than the market. However, during the bear market, the loss of holding Insight Molecular is expected to be smaller as well. Insight Molecular right now retains a risk of 4.87%. Please check out Insight Molecular value at risk, as well as the relationship between the skewness and day median price , to decide if Insight Molecular will be following its current trending patterns.

Risk-Adjusted Performance

Soft

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Insight Molecular Diagnostics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly strong fundamental indicators, Insight Molecular is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more

Actual Historical Performance (%)

One Day Return
0.75
Five Day Return
1.21
Year To Date Return
(6.56)
Ten Year Return
(89.92)
All Time Return
(95.86)
Last Split Factor
1:20
Last Split Date
2023-07-25
1
Insight Molecular Diagnostics Inc Q3 2025 Earnings Call Highlights Pioneering Advances ...
11/12/2025
2
How Insight Molecular Diagnostics Inc. stock trades under stagflation - 2025 Sector Review Precise Swing Trade Alerts - newser.com
11/19/2025
3
Acquisition by Riggs Josh of 800000 shares of Insight Molecular at 0.2132 subject to Rule 16b-3
11/20/2025
4
Is Insight Molecular Diagnostics Inc. stock considered safe haven - July 2025 Catalysts Risk Adjusted Buy and Sell Alerts - ulpravda.ru
12/19/2025
5
Needham reiterates Buy rating on Insight Molecular stock, cites progress on GraftAssureDx - Investing.com
01/05/2026
6
iMDx Announces JPM Week and BTIG Snowbird Conference Participation
01/07/2026
7
Disposition of 12175 shares by Andrea James of Insight Molecular at 6.01 subject to Rule 16b-3
01/08/2026
8
The Score Constellation, Chevron, Lockheed Martin and More Stocks That Defined the Week - The Wall Street Journal
01/09/2026
9
Analysts Offer Insights on Healthcare Companies BillionToOne, Inc. Class A and Dexcom - The Globe and Mail
01/21/2026
Begin Period Cash Flow11.1 M
Total Cashflows From Investing Activities-512 K

Insight Molecular Relative Risk vs. Return Landscape

If you would invest  680.00  in Insight Molecular Diagnostics on November 8, 2025 and sell it today you would lose (16.00) from holding Insight Molecular Diagnostics or give up 2.35% of portfolio value over 90 days. Insight Molecular Diagnostics is currently generating 0.0759% in daily expected returns and assumes 4.8749% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Insight, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Insight Molecular is expected to generate 6.37 times more return on investment than the market. However, the company is 6.37 times more volatile than its market benchmark. It trades about 0.02 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Insight Molecular Target Price Odds to finish over Current Price

The tendency of Insight Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 6.64 90 days 6.64 
about 35.72
Based on a normal probability distribution, the odds of Insight Molecular to move above the current price in 90 days from now is about 35.72 (This Insight Molecular Diagnostics probability density function shows the probability of Insight Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Insight Molecular has a beta of 0.0435. This usually indicates as returns on the market go up, Insight Molecular average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Insight Molecular Diagnostics will be expected to be much smaller as well. Additionally Insight Molecular Diagnostics has an alpha of 0.2781, implying that it can generate a 0.28 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Insight Molecular Price Density   
       Price  

Predictive Modules for Insight Molecular

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Insight Molecular. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Insight Molecular's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
1.756.7211.69
Details
Intrinsic
Valuation
LowRealHigh
0.625.5910.56
Details
Naive
Forecast
LowNextHigh
2.497.4612.42
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.24-0.24-0.24
Details

Insight Molecular Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Insight Molecular is not an exception. The market had few large corrections towards the Insight Molecular's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Insight Molecular Diagnostics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Insight Molecular within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.28
β
Beta against Dow Jones0.04
σ
Overall volatility
0.82
Ir
Information ratio 0.05

Insight Molecular Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Insight Molecular for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Insight Molecular can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Insight Molecular had very high historical volatility over the last 90 days
Insight Molecular has a very high chance of going through financial distress in the upcoming years
Insight Molecular Diagnostics was previously known as OncoCyte Corp and was traded on NASDAQ Exchange under the symbol OCX.
The company reported the previous year's revenue of 1.88 M. Net Loss for the year was (60.66 M) with profit before overhead, payroll, taxes, and interest of 2.09 M.
Insight Molecular generates negative cash flow from operations
About 56.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Analysts Offer Insights on Healthcare Companies BillionToOne, Inc. Class A and Dexcom - The Globe and Mail

Insight Molecular Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Insight Stock often depends not only on the future outlook of the current and potential Insight Molecular's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Insight Molecular's indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding13.1 M
Cash And Short Term Investments8.6 M

Insight Molecular Fundamentals Growth

Insight Stock prices reflect investors' perceptions of the future prospects and financial health of Insight Molecular, and Insight Molecular fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Insight Stock performance.

About Insight Molecular Performance

Evaluating Insight Molecular's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Insight Molecular has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Insight Molecular has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 150.83  150.58 
Return On Tangible Assets(3.41)(3.24)
Return On Capital Employed(2.52)(2.40)
Return On Assets(1.99)(1.89)
Return On Equity 4.45  4.67 

Things to note about Insight Molecular performance evaluation

Checking the ongoing alerts about Insight Molecular for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Insight Molecular help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Insight Molecular had very high historical volatility over the last 90 days
Insight Molecular has a very high chance of going through financial distress in the upcoming years
Insight Molecular Diagnostics was previously known as OncoCyte Corp and was traded on NASDAQ Exchange under the symbol OCX.
The company reported the previous year's revenue of 1.88 M. Net Loss for the year was (60.66 M) with profit before overhead, payroll, taxes, and interest of 2.09 M.
Insight Molecular generates negative cash flow from operations
About 56.0% of the company shares are owned by institutional investors
Latest headline from news.google.com: Analysts Offer Insights on Healthcare Companies BillionToOne, Inc. Class A and Dexcom - The Globe and Mail
Evaluating Insight Molecular's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Insight Molecular's stock performance include:
  • Analyzing Insight Molecular's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Insight Molecular's stock is overvalued or undervalued compared to its peers.
  • Examining Insight Molecular's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Insight Molecular's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Insight Molecular's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Insight Molecular's stock. These opinions can provide insight into Insight Molecular's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Insight Molecular's stock performance is not an exact science, and many factors can impact Insight Molecular's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Additional Tools for Insight Stock Analysis

When running Insight Molecular's price analysis, check to measure Insight Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Insight Molecular is operating at the current time. Most of Insight Molecular's value examination focuses on studying past and present price action to predict the probability of Insight Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Insight Molecular's price. Additionally, you may evaluate how the addition of Insight Molecular to your portfolios can decrease your overall portfolio volatility.